AcelRx Pharmaceuticals (ACRX)
Add to Watchlists Create an AlertAcelRx Pharmaceuticals Enterprise Value:
248.90M for May 24, 2013AcelRx Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 24, 2013 | 248.90M |
| May 23, 2013 | 233.63M |
| May 22, 2013 | 226.55M |
| May 21, 2013 | 194.53M |
| May 20, 2013 | 196.76M |
| May 17, 2013 | 204.96M |
| May 16, 2013 | 223.95M |
| May 15, 2013 | 221.34M |
| May 14, 2013 | 220.59M |
| May 13, 2013 | 191.92M |
| May 10, 2013 | 190.43M |
| May 9, 2013 | 183.73M |
| May 8, 2013 | 175.91M |
| May 7, 2013 | 192.29M |
| May 6, 2013 | 180.38M |
| May 3, 2013 | 171.81M |
| May 2, 2013 | 173.30M |
| May 1, 2013 | 162.88M |
| April 30, 2013 | 174.42M |
| April 29, 2013 | 175.91M |
| April 26, 2013 | 174.79M |
| April 25, 2013 | 175.91M |
| April 24, 2013 | 180.38M |
| April 23, 2013 | 185.22M |
| April 22, 2013 | 175.54M |
| April 19, 2013 | 174.42M |
| April 18, 2013 | 165.11M |
| April 17, 2013 | 159.90M |
| April 16, 2013 | 163.25M |
| April 15, 2013 | 171.44M |
| April 12, 2013 | 180.75M |
| April 11, 2013 | 179.63M |
| April 10, 2013 | 162.13M |
| April 9, 2013 | 161.76M |
| April 8, 2013 | 151.71M |
| April 5, 2013 | 143.51M |
| April 4, 2013 | 138.67M |
| April 3, 2013 | 141.28M |
| April 2, 2013 | 140.16M |
| April 1, 2013 | 139.05M |
| March 28, 2013 | 147.44M |
| March 27, 2013 | 149.66M |
| March 26, 2013 | 150.03M |
| March 25, 2013 | 150.40M |
| March 22, 2013 | 153.37M |
| March 21, 2013 | 139.66M |
| March 20, 2013 | 130.39M |
| March 19, 2013 | 123.35M |
| March 18, 2013 | 130.76M |
| March 15, 2013 | 127.43M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
ACRX Enterprise Value Benchmarks
| Companies | |
|---|---|
| Astex Pharmaceuticals | 365.02M |
| Cyanotech Corporation | 30.03M |
| Intercept Pharmaceuticals | 467.16M |
ACRX Enterprise Value Rankings
| Overall |
58th percentile 3142 of 7600 |
| Sector |
53rd percentile 302 of 653 in Healthcare |
| Industry |
58th percentile 22 of 53 in Drug Manufacturers - Major |
ACRX Enterprise Value Range, Past 5 Years
| Minimum | 14.40M | Dec 30 2011 |
| Maximum | 248.90M | May 24 2013 |
| Average | 71.52M |
ACRX News
Street Insider May 21